Multiphasic Neuromyelitis Optica and Life-threatening: A Case Repport
Clinical Neurology and Neuroscience
Volume 1, Issue 2, May 2017, Pages: 38-40
Received: Feb. 25, 2017; Accepted: Apr. 5, 2017; Published: Apr. 30, 2017
Views 1378      Downloads 67
Authors
Patrice Ntenga, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Salaheddine Mourabit, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Soumaila Boubacar, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Ousmane Cissé, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Mouhamed Lelouma Mansare, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Kamadore Touré, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal; Department of Preventive Medecine and Public Health, Faculty of Medicine, Pharmacy and Odontostomatology, University of Cheikh Anta Diop, Dakar, Senegal
Ndiaye Moustapha, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Mouhamadou Mansour Ndiaye, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Article Tools
Follow on us
Abstract
Neuromyelitisoptica is an inflammatory and demyelinating disease of the central nervous system that affects astrocytes in the optic nerve and the spinal cord. It is characterized by outbreaks of transverse myelitis and retro bulbar optic neuropathy with a pejorative aspect in terms of prognosis and prognosis in the short and medium term. We report the case of A S, 32 years old, male, Senegalese living in Dakar, hospitalized in June 2016 at the neurological clinic of the CHU of FANN, Dakar-Senegal for aneuromyelitisoptica. Magnetic resonance imaging showed cervical myelitis extended to the thoracic cord. The search for antibodies to aquaporin 4 was positive, the visual evoked potential showed P100 latency. Lumbar puncture performed, showed a protein content to 0.73 g/l and 10 elements (cells). The patient was placed under corticosteroid therapy. His clinical picture was stationary in the short term, with a recovery of the walk at 5 months of the appointment.
Keywords
Multiphasic, Neuromyelitis, Optica, Life-threatening
To cite this article
Patrice Ntenga, Salaheddine Mourabit, Soumaila Boubacar, Ousmane Cissé, Mouhamed Lelouma Mansare, Kamadore Touré, Ndiaye Moustapha, Mouhamadou Mansour Ndiaye, Multiphasic Neuromyelitis Optica and Life-threatening: A Case Repport, Clinical Neurology and Neuroscience. Vol. 1, No. 2, 2017, pp. 38-40. doi: 10.11648/j.cnn.20170102.13
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Jarius and Wildemann. The history of neuromyelitisoptica. Journal of Neuroinflammation 2013, 10:8.
[2]
Masoud Etemadifar et al. Prevalence of NOM globally, 2015.
[3]
Sofiane Bourmatte, Assia Boulefkhad, Yamina Sifi, Naima Taghane, M’zahem Abderrahim, Abdelmadjid Hamri Neurologie, CHU de Constantine, Constantine, Algérie, Revue Nseurologie 172 S(2016) A5-A53.
[4]
Collogue N, Marignier R, Zephir H, et al. Neuromyelistisoptica in France; a multicenter study of 125 patients. Neurology, 2010: 736-42.
[5]
Wingerchuk DM et al, Revised diagnostic criteria for Neuro-myelitis optica. Neurology 2006; 66:1485-9.
[6]
Samy, Université Cheikh Anta Diop service de neurologie, Mémoire No 944, 2014.
[7]
J Seze, Stojkovic T, Ferriby D, et al. Devic’sneuromyelitisoptica: clinical, laboratory, MRI and outcome profile. JNeurolSci 2002; 197: 57-61.
[8]
Wingerchuck D, Hogancamp WF, O’Brien PC, Weinshenker B. The clinical course of neuromyelitisoptica (Devic’s syndrome). Neurology 1999; 53:1107-14.
[9]
Raphaël Bernard-Valnet, Romain Marignier, Évolution du spectre de la neuromyélite optique de Devic, Presse Med. 2015; 44: 401–410).
[10]
P. Cabre Épidémiologie descriptive de la neuromyélite optique dans le bassin caraïbéen - 16/09/09.
[11]
V. Déral-Stéphant, C. Roux-Lelièvre, R. Vignal, E. Stéphant, A. Faivre, P. Alla, Neuromyélite optique de Devic: discussion diagnostique après dix ans d’évolution d’une neuropathie optique bilatérale sévère, J Fr. Ophtalmol., 2008; 31, 7, 705-709)
[12]
Ghezzi A, Bergamaschi R, Martinelli V et al., clinical characteristics caurse and prognosis of relapsing Devic’s Neuromyélitisoptica. J Neurol 2004; 251: 47-52)
[13]
Marignier R, De Se`ze J, Vukusic S, Durand-Dubief F, Ze´phir H, Vermersch P, et al. NMO-IgG and Devic’sneuromyelitisoptica: a French experience. Mult Scler 2008;14:440–5.
[14]
Cabrera-Gomez JA, Saiz Hinarejos A, Graus F, et al., Brain magnetic resonance imaging findings in acute relapses of neurmyelitisoptica spectrum disorders. Mult sclera, 2008; 14: 248-51.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186